
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity, formed from the rebranding of PerkinElmer, has exhibited a materially improved growth rate and margin profile, bolstered by strategic acquisitions, including BioLegend and EUROIMMUN, which enhance its life sciences and immunodiagnostics franchises. The company's ongoing shift from TST to IGRA is expected to contribute to annual market growth, alongside the expansion of its high-growth software segment, Signals, which accounts for approximately 10% of sales and offers recurring revenue potential. Furthermore, operational efficiencies and strong demand in its key markets—particularly in the US, which represents around 40% of revenue—position Revvity favorably for continued profitability and market share gains in the biopharma and diagnostics sectors.
Bears say
Revvity's stock faces a negative outlook primarily due to declining revenues, particularly in China, where Immunodiagnostics experienced a significant drop in sales, contributing to an overall revenue decline. The potential for slower customer demand is heightened by adverse economic conditions and funding cuts, which may further hamper market share and growth prospects. Additionally, macroeconomic challenges, such as product shortages and inflationary pressures across the supply chain, could further impede Revvity's operational efficiency and product delivery.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares